Together we will beat cancer

Donate

Common anti-inflammatory drug could boost cancer immunotherapy

Widely-used anti-inflammatory drugs make tumours in mice more responsive to treatments that harness the power of the body’s own immune system to tackle cancer, according to research funded by Cancer Research UK and published in the journal Cancer Discovery.

Read More

New drug targeting high-risk children’s cancer is ready for trials

A new drug that has passed safety tests in adults is likely to be effective against the aggressive childhood cancer neuroblastoma.

Read More

Breast and ovarian cancer drug effective in advanced prostate cancer

A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.

Read More

New technique allows scientists to ‘listen in’ on cancer cells

Scientists have a developed a new technique to decipher how millions of cells are communicating with each other in miniature tumours grown in the lab.

Read More

Cancer Research UK announces drug discovery collaboration with Celgene Corporation

Cancer Research UK announces the signing of a five-year drug-discovery collaboration between its subsidiary, Cancer Research Technology, and Celgene Corporation

Read More

Scientists exploit leaks in blood brain barrier to treat glioblastoma

An ovarian cancer drug can leak through the blood brain barrier to reach brain tumours and could be an effective treatment for glioblastoma.

Read More

Immunotherapy and targeted drugs could stop some melanomas from returning

Two clinical trials have found that existing treatments for advanced melanoma could stop the cancer returning in some people with earlier stage disease.

Read More

Cancer Research UK and Biotecnol to trial new immuno-oncology treatment for advanced tumours

Cancer Research UK and Biotecnol Limited will trial an experimental immuno-oncology treatment for some patients with advanced tumours.

Read More

Adding abiraterone to standard treatment improves prostate cancer survival by 40 per cent

Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent.

Read More

Targeted drug delays relapse of intermediate-stage lung cancer

A drug holds lung cancer at bay longer after surgery than standard chemotherapy, according to unpublished results of a new trial in China.

Read More